## Amendments to the Claims:

Please cancel claims 14, 15, 18, 19, 27, 28, 30-33, 42, 45 and 48-51, and amend claims 17, 22, 43 and 44, as shown in the listing of claims that follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-16 (canceled).

17. (Currently amended) The pharmaceutical composition of claim 45 44, wherein the biologically active agent is selected from the group consisting of:

3-(2,6-Dimethylbenzyloxy)phenylacetic acid;

3-(2,6-Dimethylbenzyloxy)benzoic acid;

Ethyl-3 (2.6 dimethylbenzyloxy)benzoute:

6-[3-(2,6-Dimethylbenzyloxy)-phenyl]-hexanoic acid;

Ethyl 6-[3-(2.6-dimethylbenzyloxy)-phenyl]-hexanoate;

5-[3-(2.6-Dimethylbenzyloxy)-phenyl]-pentanoic acid;

Ethyl 5-[3-(2,6-dimethylbenzyloxy)-phenyl]-pentanoate;

3-[3-(2.6-dimethylbenzyloxy)phenyl]-propionic acid; and

Ethyl 3-[3-(2.6-dimethylbenzyloxy)phenyl]-propanoate.

Claims 18-21 (canceled).

22. (Currently amended) The biologically active agent of claim 49 47, selected from the group consisting of:

3-(2.6-Dimethylbenzyloxy)phenylacetic acid;

6-[3-(2,6-Dimethylbenzyloxy)-phenyl]-hexanoic acid;

Ethyl 6-[3-(2,6-dimethylbenzyloxy)-phenyl]-hexanoate;

5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pentanoic acid;

Patent Application No. 10/531,630 Amendment dated January 8, 2009 Page 3

Ethyl 5-[3-(2.6-dimethylbenzyloxy)-phenyl]-pentanoate: 3-[3-(2,6-dimethylbenzyloxy)phenyl]-propionic acid; and Ethyl 3-[3-(2.6-dimethylbenzyloxy)phenyl]-propanoate.

Claim 23 (canceled).

Claim 24 (canceled).

- 25. (Previously presented) The pharmaceutical composition of claim 17. wherein the biologically active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
- 26. (Previously presented) The biologically active agent of claim 22. being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.

Claims 27-42 (canceled).

43. (Currently amended) A pharmaceutical composition adapted for oral administration, comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent, wherein the agent is a compound of the formula:

$$A(CH_2)_{\mathfrak{l}}(N)_{\mathfrak{l}}(CH_2)_{\mathfrak{n}} - O$$

$$(CH_2)_{\mathfrak{m}} OR^1$$

wherein

n is 1 or 2;

Patent Application No. 10/531,630 Amendment dated January 8, 2009 Page 4

m is [[0,]] 1, 2, 4, or 5;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is 2.6-dimethylphenyl; phenyl, substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by

and

methyl or ethyl;

R<sup>1</sup> is hydrogen or alkyl having 1 or 2 carbon atoms;

or when R<sup>1</sup> is hydrogen, a pharmaceutically acceptable salt of the compound.

44. (Currently amended) The pharmaceutical composition of claim 43, wherein n is 1; q is 0; t is 0; R<sup>3</sup> is hydrogen; and A is 2.6-dimethylphenyl, phenyl, substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

Claim 45 (canceled).

Patent Application No. 10/531,630 Amendment dated January 8, 2009 Page 5

- 46. (Previously presented) The pharmaceutical composition of claim 43 in oral dosage form.
- 47. (Previously presented) A biologically active agent, wherein the agent is a compound of the formula:

$$A(CH_2)_{\mathbf{i}}(N)_{\mathbf{q}}(CH_2)_{\mathbf{n}} - O$$

$$(CH_2)_{\mathbf{m}} O$$

$$O$$

wherein

n is 1 or 2:

m is 1, 2, 4, or 5;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is 2.6-dimethylphenyl: and

R<sup>1</sup> is hydrogen or alkyl having 1 or 2 carbon atoms;

Patent Application No. 10/531.630 Amendment dated January 8, 2009 Page 6

or when R<sup>1</sup> is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is substantially pure.

Claims 48-51 (canceled).

and the state of t